Table 1.

Baseline demographic characteristics, laboratory and treatment-related measures in the cohort

Age, yr (mean ± SD)60.1 ± 15.1
Duration of ESRD, yr (mean ± SD)3.6 ± 3.6
Gender
    male, %50.6
    female, %49.4
Race, %
    white48.9
    black44.7
    Native American0.7
    Asian/Pacific Islander1.6
    other4.2
Diabetes mellitus, %
    adult onset40.5
    juvenile onset4.5
    none55
Laboratory measures at 3 mo (mean ± SD)
    hemoglobin, g/dl10.2 ± 1.2
    urea reduction ratio, %67.3 ± 7.0
    Kt/V1.4 ± 0.2
    albumin, g/dl3.9 ± 0.4
    bicarbonate, mEq/L20.6 ± 3.0
    aspartate aminotransferase, IU/L19 ± 15.5
    calcium, mg/dl9.0 ± 0.8
    phosphate, mg/dl6.0 ± 1.7
    intact PTH, pg/ml315 ± 433
    ferritin, ng/ml352 ± 402
    transferrin saturation, %26.7 ± 11.6
    iron level, μg/dl57.2 ± 24.3
Treatment measures (mean ± SD)
    intravenous iron dose summed over 3 mo, mg944 ± 546
    erythropoietin dose average over 3 mo, U50,875 ± 32,238
  • N = 34,963 patients.